tcr publications pipeline car tcr collaborations national cancer institute netherlands cancer institute adimab alpine immune sciences amgen bluebird bio cell design labs genentech general electric leiden university medical center leukemia & lymphoma society tel aviv sourasky medical center the ucla david geffen school of medicine investors press releases events & presentations corporate governance financials & filings sec filings annual reports & proxies quarterly results key ratios stock information investor faqs careers contact focused on the cure focused on the team focused on the science focused on manufacturing technology our engineered autologous cell therapy eacttm technology allows us to harness the power of a patient s own immune system to target and kill cancer cells . our platform has the potential to address both hematological blood based and solid tumor cancers . watch car and tcr videos pipeline we are developing an industry leading pipeline of chimeric antigen receptor car and t cell receptor tcr engineered t cells . we are currently enrolling four pivotal studies for kte c19 our most advanced product candidate . news kite pharma appoints chris nowers as head of europe to lead commercial operations and advance the company s car tcr therapry portfolio in the region read more sitemapabout management team board of directors scientific advisory board special advisors technology scientific platform car & tcr publications pipeline car tcr collaborations national cancer institute netherlands cancer institute adimab alpine immune sciences amgen bluebird bio cell design labs genentech general electric leiden university medical center leukemia & lymphoma society tel aviv sourasky medical center the ucla david geffen school of medicine investors press releases events & presentations corporate governance financials & filings sec filings annual reports & proxies quarterly results key ratios stock information investor faqs careers contact for inquiries clinical trials clinicaltrials kitepharma.com 310 742 2867 investors investors kitepharma.com 310 742 2870 business development business kitepharma.com media media kitepharma.com product complaints productcomplaints kitepharma.com 310 742 2901 kitepharma linkedin 2016 copyright kite pharma terms and conditions privacy policy scroll to top